Position title: Associate Dean for Therapeutics Development
We have developed a novel immune evasive technology that allows transplantation of allogeneic and xenogeneic islets into immune competent recipients (murine and canine) without need of immune suppression. A provisional patent has been filed (assigned to WARF) and scientific paper is under review. A collaboration with the UW transplant Center (Jon Odorico) and diabetes experts (Dawn Davis) is underway to reduce this technology to practice with ES-derived islet-like cells and xeno-sourced porcine islets (Dixon Kaufman) to advance a potential cure for diabetes. A new U01 grant application related to this work is under review at NIAID.